Calcium-channel blockers in acute hypertension

Area of Science:

• Cardiology
• Pharmacology

Background:

• Acute hypertension presents with diverse dysfunctions, necessitating careful selection of antihypertensive agents.
• No single agent is ideal due to varied clinical settings, mechanisms, and end-organ damage.

Purpose of the Study:

• To compare the efficacy and safety of calcium channel blockers (verapamil, nifedipine) with other antihypertensive drugs for acute hypertension.
• To evaluate key parameters including onset, duration, side effects, contraindications, and long-term utility.

Main Methods:

• Review and comparison of verapamil and nifedipine against nitroprusside, diazoxide, hydralazine, labetalol, and clonidine.
• Analysis based on intravenous and oral/buccal administration routes.

Main Results:

• Intravenous verapamil demonstrates rapid onset, reasonable duration, good side effects, and long-term usefulness.
• Oral/buccal nifedipine shows versatility, rapid onset, reasonable duration, minimal hypotension risk, few contraindications, and excellent safety.
• Both verapamil and nifedipine compare favorably with existing agents based on extensive global experience.

Conclusions:

• Verapamil and nifedipine are effective and well-tolerated options for managing acute hypertension.
• These calcium channel blockers offer a favorable risk-benefit profile for diverse patient populations.